Multiple sclerosis (MS) is thought to be an autoimmune T-cell-mediated disease directed at myelin antigens of the central nervous system. Besides myelin proteins, lipid components of CNS are supposed to playa role as antigens for T cells in MS. CDI is a family of MHC-like glycoproteins specialized in capturing and presenting a variety of microbial and self lipids and glycolipids to antigen-specific T cells. CD L-restricted T cells specific for gangliosides and sulfatide have been isolated from subjects with MS and in mice with experimental allergic encephalopathy. We genotyped exon 2 of CDIA and CDIE in 205 MS patients and 223 unrelated healthy controls and determined their association with the presence of anti-ganglioside and anti-sulfatide antibodies. CDIE 01-01 is associated with a reduced risk ofMS (OR 0.54, p=O.OOI); CDIA 02-02 (OR 1.99, p=0.012) or CDIE 02-02 (OR 2.45, p=O.OOO) with an increased risk. The combination of the genotypes CDIA 02-02 and CDIE 02-02 is present in 90.7% of patients but in only 9.4% controls (OR 94.16, p= 0.000). CDIA and CDIE polymorphisms contribute to the polygenic susceptibility to MS. The functional effects of CDI polymorphisms are unknown, however changes in CDI alleles may affect numerous immunological functions.
Multiple Sclerosis (MS) is a complex demyelinating disorder ofthe central nervous system (1). Environmental influences and genetic factors are implicated in the risk of developing MS. The idea that genetic factors may playa role in MS was first raised in the 1890's with the identification of familial aggregation (2) . The data from twin studies indicate a strong familial factor in MS, with a concordance rate for monozygotic twins of about 20% (range 0-40%) (3) . More than 20 whole genome studies have been performed employing up to 6,000 microsatellite markers and different methodologies in different MS populations (4) . The strongest association was found for one or more susceptibility genes on chromosome 6p21 in the area of the major histocompatibility complex (MHC) (5) . More recently, genome-wide association studies have described polymorphisms within genes related to the regulation of the immune response not MHC-dependent (6) . All the newly identified MS risk alleles are common, exert only modest individual effects on risk (odds ratios 1.1-1.3) and act independently (6) .
Several myelin peptides, processed and presented to cells of the immune system by the MHC class I and II, have been implicated in the pathogenesis of MS (5) . However, lipids comprise over 70% of myelin, and the presence of T-cell and autoantibody reactivity to gangliosides and sulfatides in MS patients suggests that an autoimmune response to glycolipids may contribute to the pathogenesis (7) (8) (9) (10) . The COl antigen-presenting molecules are a conserved family of MHC-like transmembrane glycoproteins which are specialized in capturing and presenting a variety of microbial and selfglycolipids to antigen-specific T cells (11). There are five closely linked CD I genes in humans located in chromosome I (q22-23) and named COlA, B, C, 0, and E (11). Allelic polymorphism of CD I genes is limited although all five genes are polymorphic in exon 2 codifying for the a I domain of CD I molecules (12) (13) . T cells specific for different self glycosphingolipids and restricted by all types of CD I molecules have been identified in MS patients (14) . CD 1 expression is increased in both MS plaques and experimental allergic encephalomyelitis lesions and an increased number of dendritic cells expressing CD Ia has been reported in MS patients (15) (16) (17) .
The above observations prompted us to investigate by a candidate-gene approach the role of CD I gene polymorphisms in the susceptibility to MS.
MATERIALS AND METHODS

Patients
The study included 205 unrelated MS patients (122 females and 83 males). All patients had definite MS according to revised McDonald's criteria (18) . Mean age was 41+9 years (range 19 to 70 years). According to the consensus definition of clinical course, 144 patients had relapsing remitting MS (RR), 33 had secondary progressive MS (SP), and 28 had primary progressive MS (PP) (19) . Two hundred twenty-three unrelated, randomly selected, healthy subjects from the same geographic area constituted the control group for genetic studies. A written informed consent was obtained from each subject and the study was approved by the local Ethics Committee.
Determination of anti-ganglioside and anti-sulfatide antibodies
Serum antibodies (Abs) (lgG and IgM) to gangliosides GM I, GD Ia, GM2, GD Ib, and sulfatide were tested in all patients by ELISA, as described (20) . The positivity was assigned at a titer > I:400 for gangliosides and at a titer ::::1 :6400 for sulfatide.
Genetic analysis
All five genes (CDIA, B, C, D, and E) have been reported to be polymorphic in exon 2 but the substitutions of CDiB and CDiC genes are silent (12) . CDID was found to be monomorphic in both controls and Guillain-Barre syndrome patients in a previous study (20) . We restricted the study, therefore, to the exon 2 of CD IA and CD IE genes both in healthy subjects and MS patients, according to the methods previously reported (20) .
Statistical analysis
Associations may be spurious in genetic case--eontrol studies if the distribution of genotypes deviates from Hardy-Weinberg equilibrium (HWE). HWE depends on a series of assumptions about the population tested, including, for example, no new mutation, no selection, and random mating. Departures from HWE, if not due to chance or violation of these assumptions, therefore, may point to genotyping error or other biases (21) (22) . Deviations from HWE were tested separately using an asymptotic X2 test in controls and among patients, applying the Yates' correction.
Since CD IA was 01-0 I homozygous only in 2 patients and 4 controls, the value of p of the chi-square could be underestimated. In such cases, a significant difference might be due to the inaccuracy of the statistical test used rather than to a real departure from the Hardy-Weinberg equilibrium. For this reason a Monte Carlo randomization test was also used to evaluate the deviation from equilibrium (23) . The randomization test was calculated using the on-line software made available on the internet by R. Lowry (24) and running 10,000 iterations of the sampling.
The association between CD I genotypes and presence/ absence of the disease and presence/absence of antiganglioside and anti-sulfatide antibodies and the different sub-groups of MS, were evaluated using odds ratio and Fisher's exact test. The frequency of each genotype was compared to the overall frequency of the other genotypes in patients and controls. The Bonferroni adjustment was used to control type I error in multiple tests. The thresholds for 2-tailed statistical significance in each Fisher's test was adjusted to 0.01667 to obtain in 3 tests an overall alpha level of 0.05 in the case of CD IE, which has 3 different genotypes. The choice to use Bonferroni adjustment was based on the consideration that, despite the shortcomings highlighted in this procedure, the evaluation of association of a disease with genotypes is one of the few situations in which Bonferroni adjustment is acceptable (25) . Moreover, Bonferroni correction assumes the independence of all tests performed. In many association studies markers are not independent, therefore the choice of using Bonferroni correction is conservative (26) .
The same method was followed to evaluate the association between genotype combinations and MS. Since only three combinations were considered as relevant, the thresholds for statistical significance in each Fisher's test was adjusted to 0.01667 to obtain in 3 tests an overall alpha level of 0.05.
The power of the tests performed was estimated according to Dupont 
RESULTS
The clinical sub-groups and the association with antibodies are reported in Table I . One-hundred twelve (54.6%) patients had at least one antiganglioside antibody, 93 (45.4%) patients had antisulfatide antibodies and 145 (70.7%) patients had at least one antibody.
The HWE was not violated by the control group or the patients for either of the two genes (Table II) . The expected cumulative probability of the multinomial distribution of the two genes considered, generated through a Montecarlo simulation was 0.32 for COlA and 0.994 for COlE in controls, 0.09 for COlA and 0.57 for COlE in patients respectively. Therefore, neither test detected any violation of the HWE.
In Table III the frequencies are reported of COlA and COlE alleles and genotypes in controls and patients. The gene COlA is biallelic, allele 02 being the more frequent in both controls and patients. The genotype CD IA 01-01 was poorly represented in controls and patients. The genotype COlA 01-02 was more frequent in controls and the genotype CD IA 02-02 was more frequent in patients. However the frequency of genotype COlA 02-02 was significantly higher than in controls only in the sub-group of the 177 RR+SP patients (Table  IV) . There were no differences in the frequencies of the COlA 02-02 between the 223 controls and the 144 RR patients, the 33 SP patients, the 28 PP patients, the 145 patients positive for at least one of the antibodies tested, the 112 patients positive for at least one anti-ganglioside antibody, and the 93 patients positive for anti-sulfatide antibodies. In addition, no difference in the COlA 02-02 genotype was observed between the 145 patients positive for at least one of the antibodies and the 60 negative patients (Table IV) .
The COlE gene presented two alleles, allele 01 was more frequent in controls whereas the allele 02 was more frequent in patients (Table III) . The genotype CD lEO 1-02 was present with similar frequency in both controls and patients. The frequency ofgenotype CD 1EO1-01 was significantly higher in controls (Table V) . The frequency of genotype CD IE 01-01 was also significantly higher in controls than in the 144 RR patients, in the 177 RR+SP patients and in the 112patients positive for at least one anti-ganglioside antibody (Table V) . There was no significant difference in the frequencies of the genotype COlE 01-01. between controls and the 33 SP and the 28 PP patients, the 145 patients positive for at least one of the antibodies, the subgroups of the 93 patients positive for anti-sulfatide antibodies and also between the 145 patients positive for at least one of the antibodies tested and the 60 patients without antibodies (Table V) .
The frequency of genotype CD IE 02-02 was significantly higher in all MS patients, in the 144 RR and the 177 RR+SP patients, in the 145 patients positive for at least one ofthe antibodies tested, in the 112 patients positive for anti-ganglioside antibodies and in the 93 patients positive for anti-sulfatide antibodies than in controls (Table VI) . There is no significant difference in the frequencies of the genotype COlE 02-02 between the 33 SP and the 28 PP patients and controls (Table VI ). No significant difference was observed between the 145 patients positive for at least one of the antibodies tested and the 60 patients without antibodies (Table VI) .
The combination of the genotypes COlA 02-02 and COlE 02-02 is present in 186 (90.7%) patients but only in 21 (9.4%) controls. This difference is highly statistically significant (OR 94.16, p = 0.000).
The study was based on 205 patients and 223 controls for both genes considered. The statistic used to evaluate the null hypothesis was the Fisher's exact test, and the Type I error probability associated with 
DISCUSSION
We found that the genotype CD 1A 02-02 was more frequent in the 177 RR+SP patients than in controls and can be considered as a risk factor for this sub-group of MS. The functional effects of CD 1A polymorphisms are unknown. In the CD 1A gene the allele 01 contains, with respect to allele 02, two linked substitutions at position 13 and 51 in thẽ pleated sheet region of the a domain (12) . CD I molecules are expressed as type I proteins on the cell surface in association with~2-microglobulin,which is necessary for correct folding and maturation of NS: not significant; *: statistically significant at the Bonferroni threshold 0.0167; Ah: Antihody; RR: relapsing-remitting; SP: secondary progressive; PP: primary progressive. vs: versus; Cil.: confidence interval these molecules (28) (29) . Crystal structure of CD 1a is characterized by the presence of three domains (30) . Domains I and 2 are disposed to form a classic MHC antigen-binding-like domain in the part of the protein most distal from the membrane. The two domains show two antiparallel a elices defining a groove, which is narrower and deeper than the antigen-binding groove present in classic MHC molecules. Two large pockets surrounded by nonpolar aminoacids are present below the CD 1 groove. Due to the hydrophobic nature of their walls, the two pockets are likely to permit insertion of the lipid tails in the CD l-presented antigens. Domain 3 is more membrane-proximal and interacts in a non-covalent manner with the~2-microglobulin partner (31) . CD 1A Oland 02 are efficiently expressed on the cell surface (32) and, COlA polymorphism 02-02 could affect the ability to form disulfide bonds creating a different stability of the complex for the association of accessory molecules and/or the hydrophobicity and may have an impact upon the interaction with~2-microglobulin (12) . Alternatively, CD 1A polymorphism 02-02 may influence the capability of the microsomal chaperon triglyceride transfer protein, resident in the endoplasmatic reticulum, to load self-lipids onto COla and affect the capacity of the endogenous and exogenous presentation to lipid specific T cells (33) .
The frequency of genotype CD lEO 1-01 is significantly higher in controls than in MS patients. The significantly higher frequency of CD lEO 1-01 was also demonstrated when controls were compared to the patients positive for anti-ganglioside antibodies, the RR patients and the RR+SP subgroup. These observations suggest that the CD IE 01-01 genotype may have a protective role in MS. On the other hand, the genotype CD IE 02-02 is more frequent in MS patients than in controls. The statistically significant association remains also in all the MS sub-groups, except in the SP and PP patients, suggesting that the CO 1E 02-02 genotype is a risk factor for MS. Although CD 1e is not expressed on the surface of dendritic cells, it follows an intracellular pathway, moving into Golgi's stack, after being assembled in the endoplasmic reticulum. Upon cell activation, CD 1e traffics to late endosomes without reaching the plasma membrane (34) . The absence of a cell surface distribution of CD1e strongly argues against its direct interaction with T cell receptors in antigen presentation. In late endosomes, CD Ie is cleaved and remains within this compartment as a soluble molecule and its function is to facilitate glycolipid . processing and presentation by other CD I members similar to lipid transfer proteins (35) . Gangliosides are presented by CD 1b molecules to specific T cells. GMI, which contains a large glycan, is recognized as an intact molecule and does not require any processing, as shown by the ability of recombinant CD1b proteins to present the antigen in the absence ofAPCs. More complex gangliosides, such as GO 1a, G01b, GTlb, and GQ1b are also recognized by the same T cells without processing (36) , however, an abnormal internalization of glyco1ipids might occur during phagocytosis of membrane debris. This may be the case in degenerating plaques of MS patients, where activated macrophages and dendritic cells phagocyte myelin. The accumulation of CD 1e in CD 1b compartments indicates its participation in processing and presentation of glycolipids by COlb which returns to the plasma membrane to stimulate antigen specific T cells (37) . Recent experiments showed that CD1e allows processing of microbial antigens with a large carbohydrate component (35) . Through this form of glycolipid editing, CD 1e helps to expand the repertoire of glycolipid T cell antigens to optimize antimicrobial but possibly also autoimmune responses (35) . Tourne and colleagues (38) in reporting the role ofthe COlE polymorphism in the immune response to M malmoense, demonstrated a functional defect for the allele 04 hypothesizing that the individuals homozygous for this allele might display an altered immune response to lipid antigens requiring endosomal processing. The allele COlE 02 has, with respect to COlE 01, a nucleotide substitution in codon 79 which causes an amino acid replacement of an uncharged glutamine to a positively charged arginine in the region flanking the ligand binding groove (12) . It is possible that the genotypes CD 1E 01-01 and CD1E 02-02 by inducing different charge and conformation of CD1e influence its capacity to process the glycolipids, respectively inhibiting or favouring the presentation by C01b: At last the combination of the genotypes CD IA 02-02 and COlE 02-02 is highly associated with the risk of MS possibly by combining the effects of single CD1a and CD 1e molecules changes.
This study suggest that in the complex scenario of the genetic architecture ofMS the po1ymorphisms of the CD 1 genes plays a relevant role in the polygenic susceptibility to MS.
Genetic association studies have the potential to uncover mechanisms of complex diseases.
However, variation factors such as ethnic populations or sample sizes may influence the results. Larger studies, and international collaboration, are required to identify or confirm genetic associations and susceptibilities.
